支架类型与经皮冠状动脉干预后发生心痛之间的关联
Amirali Nejat1, Alireza Hosseinpour2,3, Pouria Azami1
1Department of Cardiovascular Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
BMC cardiovascular disorders
|September 1, 2024
概括
支架类型不能预测皮肤穿冠状动脉干预 (PCI) 后的胸痛. 然而,脂质不良,先前冠状动脉疾病 (CAD) 和先前住院是PCI后心脏病的重要预测因素. 胸痛的严重程度与新的STEMI和中风相关.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 生物医学工程 生物医学工程
背景情况:
- 高达40%的患者在皮肤上冠状动脉干预后 (PCI) 经历了胸痛.
- 关于支架类型是否影响PCI后心痛症状的数据有限.
研究的目的:
- 评估支架类型是否预测PCI后的胸痛症状.
- 为了确定PCI后心脏病的其他预测因素.
主要方法:
- 在787名接受PCI的患者中收集了包括支架类型在内的重血管化特征的数据.
- 对心痛,ST段升高心肌梗塞 (STEMI) 和1,3个月和6个月的临床结果的潜在随访.
- 利用单变量和多变量逻辑回归来确定在6个月后续的胸痛预测因子.
主要成果:
- 在三种支架类型 (Orsiro,Promus,Xience) 中,PCI后心痛或新STEMI发生没有显著差异.
- 支架类型在随访期间不是心痛的预测因素.
- 脱脂症,先前的冠状动脉疾病 (CAD) 和先前的住院治疗是心痛的独立预测因素.
- 观察到Angina类恶化和新的STEMI/中风之间存在线性关联.
结论:
- 支架类型与PCI后心痛无关.
- 脱脂症,先前的CAD和先前的住院治疗是复发性心痛的关键预测因素.
- 胸痛的严重程度与新发病的STEMI和中风线性相关.
相关概念视频
Ischemic Heart Disease: Overview
1.2K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.2K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
464
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
464


